Meares CF - Search Results

1

New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor.

Feng X, Pak RH, Kroger LA, Moran JK, DeNardo DG, Meares CF, DeNardo GL, DeNardo SJ. Feng X, et al. Among authors: meares cf. Hybridoma. 1998 Apr;17(2):125-32. doi: 10.1089/hyb.1998.17.125. Hybridoma. 1998. PMID: 9627052

2

Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.

DeNardo SJ, Zhong GR, Salako Q, Li M, DeNardo GL, Meares CF. DeNardo SJ, et al. Among authors: meares cf. J Nucl Med. 1995 May;36(5):829-36. J Nucl Med. 1995. PMID: 7738660 Free article.

3

Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.

Li M, Meares CF, Zhong GR, Miers L, Xiong CY, DeNardo SJ. Li M, et al. Among authors: meares cf. Bioconjug Chem. 1994 Mar-Apr;5(2):101-4. doi: 10.1021/bc00026a001. Bioconjug Chem. 1994. PMID: 8031871

4

Antibody responses to macrocycles in lymphoma.

DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ. DeNardo GL, et al. Among authors: meares cf. J Nucl Med. 1996 Mar;37(3):451-6. J Nucl Med. 1996. PMID: 8772643 Free article.

5

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL. DeNardo SJ, et al. Among authors: meares cf. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4000-4. doi: 10.1073/pnas.94.8.4000. Proc Natl Acad Sci U S A. 1997. PMID: 9108094 Free PMC article.

6

Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.

DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL. DeNardo SJ, et al. Among authors: meares cf. J Nucl Med. 1998 May;39(5):842-9. J Nucl Med. 1998. PMID: 9591587 Free article.

7

Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.

Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF. Kukis DL, et al. Among authors: meares cf. J Nucl Med. 1998 Dec;39(12):2105-10. J Nucl Med. 1998. PMID: 9867151 Free article.

8

67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.

DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ. DeNardo GL, et al. Among authors: meares cf. Clin Cancer Res. 1999 Mar;5(3):533-41. Clin Cancer Res. 1999. PMID: 10100704

9

Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.

Mirick GR, O'Donnell RT, DeNardo SJ, Shen S, Meares CF, DeNardo GL. Mirick GR, et al. Among authors: meares cf. Nucl Med Biol. 1999 Oct;26(7):841-5. doi: 10.1016/s0969-8051(99)00049-9. Nucl Med Biol. 1999. PMID: 10628566

10

Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.

DeNardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares CF, Goldstein DS, Shen S. DeNardo GL, et al. Among authors: meares cf. Clin Lymphoma. 2000 Sep;1(2):118-26. doi: 10.3816/clm.2000.n.010. Clin Lymphoma. 2000. PMID: 11707820

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters